$MTNB
Matinas BioPharma Holdings, Inc.

2015 Q2 Form 10-Q Financial Statement

#000114420415031549 Filed on May 15, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $77.00K $57.64K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $1.355M $1.448M $1.074M
YoY Change 21.15% 34.89%
% of Gross Profit
Depreciation & Amortization $10.00K $10.86K $9.452K
YoY Change 0.0% 14.85%
% of Gross Profit
Operating Expenses $2.479M $2.626M $2.129M
YoY Change 2.41% 23.35%
Operating Profit -$2.402M -$2.569M -$2.129M
YoY Change -0.77% 20.65%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.738K -$1.493K -$9.996K
YoY Change -49.16% -85.06%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.405M -$2.570M -$2.139M
YoY Change -0.88% 20.15%
Net Earnings / Revenue -3122.77% -4459.21%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 56.90M shares 36.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.610M $4.620M $8.560M
YoY Change -0.6% -46.03%
Cash & Equivalents $6.605M $4.617M $8.558M
Short-Term Investments
Other Short-Term Assets $220.0K $190.0K $90.00K
YoY Change 450.0% 111.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.880M $4.840M $8.650M
YoY Change 2.91% -44.04%
LONG-TERM ASSETS
Property, Plant & Equipment $363.2K $339.0K $360.0K
YoY Change 0.43% -5.82%
Goodwill $1.385M $1.385M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $220.0K $220.0K $320.0K
YoY Change -31.25% -31.25%
Total Long-Term Assets $4.982M $4.957M $680.0K
YoY Change 635.04% 629.04%
TOTAL ASSETS
Total Short-Term Assets $6.880M $4.840M $8.650M
Total Long-Term Assets $4.982M $4.957M $680.0K
Total Assets $11.86M $9.798M $9.330M
YoY Change 61.1% 5.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $745.6K $466.6K $240.0K
YoY Change 165.24% 94.43%
Accrued Expenses $339.8K $780.8K $390.0K
YoY Change -37.91% 100.22%
Deferred Revenue
YoY Change
Short-Term Debt $10.00K $10.00K $0.00
YoY Change
Long-Term Debt Due $30.00K $40.00K $40.00K
YoY Change -25.0% 0.0%
Total Short-Term Liabilities $1.136M $1.308M $670.0K
YoY Change 30.6% 95.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $40.00K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $840.0K $840.0K
YoY Change
Total Long-Term Liabilities $840.0K $840.0K $40.00K
YoY Change 2700.0% 2000.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.136M $1.308M $670.0K
Total Long-Term Liabilities $840.0K $840.0K $40.00K
Total Liabilities $3.230M $3.405M $720.0K
YoY Change 254.95% 372.9%
SHAREHOLDERS EQUITY
Retained Earnings -$19.03M -$16.62M
YoY Change 126.62%
Common Stock $5.698K $4.679K
YoY Change 78.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.629M $6.393M $8.610M
YoY Change
Total Liabilities & Shareholders Equity $11.86M $9.798M $9.330M
YoY Change 61.1% 5.01%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$2.405M -$2.570M -$2.139M
YoY Change -0.88% 20.15%
Depreciation, Depletion And Amortization $10.00K $10.86K $9.452K
YoY Change 0.0% 14.85%
Cash From Operating Activities -$2.220M -$2.320M -$2.090M
YoY Change 20.0% 11.0% 1293.33%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $4.845K $193.3K
YoY Change -42.86% -97.49%
Acquisitions -$70.75K
YoY Change
Other Investing Activities $0.00 $70.00K
YoY Change
Cash From Investing Activities -$40.00K $70.00K -$190.0K
YoY Change -42.86% -136.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.283M $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.240M 4.280M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.220M -2.320M -2.090M
Cash From Investing Activities -40.00K 70.00K -190.0K
Cash From Financing Activities 4.240M 4.280M 0.000
Net Change In Cash 1.980M 2.030M -2.280M
YoY Change -203.12% -189.04% -1050.0%
FREE CASH FLOW
Cash From Operating Activities -$2.220M -$2.320M -$2.090M
Capital Expenditures -$40.00K $4.845K $193.3K
Free Cash Flow -$2.180M -$2.325M -$2.283M
YoY Change 22.47% 1.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q1 dei Trading Symbol
TradingSymbol
MTNB
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56900670 shares
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">[2]</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">Use of Estimates</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY:Times New Roman, Times, Serif">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY:Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">[4]</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">Concentration of Credit Risk</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY:Times New Roman, Times, Serif">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY:Times New Roman, Times, Serif">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Cash balances are maintained principally at one major U.S. financial institution and are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to regulatory limits. At various times throughout the period ended March 31, 2015, the Company&#8217;s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4616529 USD
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
93626 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
4840264 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
339036 USD
CY2015Q1 us-gaap Other Long Term Investments
OtherLongTermInvestments
216395 USD
CY2015Q1 us-gaap Assets
Assets
9797746 USD
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
466620 USD
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
780840 USD
CY2015Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
44636 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1307853 USD
CY2015Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
4679 USD
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23010088 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16621875 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
6392892 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9797746 USD
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18410000 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33938000 shares
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
27100000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46775670 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32292650 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46775670 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32292650 shares
CY2013Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8250000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.04 pure
CY2014Q2 mtnb Sharebased Compensation Arrangement By Sharebased Payment Award Increase Of Shares Offering Date
SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate
January 1, 2015
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
135792 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
157321 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
160257 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
163193 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
406147 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1022710 USD
CY2014Q2 mtnb Increase Decrease In Lease Rental Expense
IncreaseDecreaseInLeaseRentalExpense
14200 USD
CY2015Q1 us-gaap Security Deposit
SecurityDeposit
300000 USD
CY2013Q4 us-gaap Lessor Leasing Arrangements Operating Leases Term Of Contract
LessorLeasingArrangementsOperatingLeasesTermOfContract
P7Y
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2175 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32000000 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35561911 shares
CY2014Q1 us-gaap Depreciation
Depreciation
9452 USD
CY2015Q1 us-gaap Depreciation
Depreciation
10856 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
273824 USD
CY2014Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
12723 USD
CY2015Q1 mtnb Security Deposits Reduced By Straight Line Basis Description
SecurityDepositsReducedByStraightLineBasisDescription
Starting June 1, 2015, this deposit can be reduced by $100,000 on an annual basis, down to $50,000, as long as the Company makes timely rental payments.
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1073781 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1448413 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1055247 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1177841 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2129028 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
2626254 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2139024 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2570111 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
332683 USD
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
41117 USD
CY2015Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
78 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-37980 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-26583 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-154441 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-104948 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2089046 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2322827 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
193277 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4845 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-193277 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
65909 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4282734 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2282323 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2025816 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10840428 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8558105 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4937500 USD
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
654766 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
274000 USD
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
333000 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1530000 shares
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
45417 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.45
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.94
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5353417 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.05
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6838000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.92
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000 USD
CY2014Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-75720 USD
CY2015Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-33347 USD
CY2014Q1 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
111095 USD
CY2015Q1 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
0 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2129028 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2568618 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9996 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1493 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-116592 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2378672 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
375000 USD
CY2013 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
1000 USD
CY2013 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
953389 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
138316 USD
CY2013 mtnb Stock Issued During Period Value Private Placement
StockIssuedDuringPeriodValuePrivatePlacement
15000000 USD
CY2013 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
470000 USD
CY2013 mtnb Adjustments To Additional Paid In Capital Restricted Stock Award Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalRestrictedStockAwardRequisiteServicePeriodRecognition
463562 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
211036 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1821402 USD
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
332683 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-3713127 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-10221045 USD
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
152751 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
10474788 USD
CY2015Q1 us-gaap Liabilities
Liabilities
3404854 USD
CY2014Q4 us-gaap Liabilities
Liabilities
1133554 USD
CY2015Q1 us-gaap Goodwill
Goodwill
1384674 USD
CY2014Q4 us-gaap Goodwill
Goodwill
0 USD
CY2015Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
3017377 USD
CY2014Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0 USD
CY2015Q1 us-gaap Notes Payable Current
NotesPayableCurrent
10000 USD
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2015Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
5757 USD
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0 USD
CY2015Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
843674 USD
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 USD
CY2015Q1 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
1253327 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
0 USD
CY2015Q1 mtnb Contract Research Receivables
ContractResearchReceivables
30109 USD
CY2014Q4 mtnb Contract Research Receivables
ContractResearchReceivables
0 USD
CY2014Q1 mtnb Contract Research Revenue
ContractResearchRevenue
0 USD
CY2015Q1 mtnb Contract Research Revenue
ContractResearchRevenue
57636 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15535 USD
CY2015Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2119689 USD
CY2015Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
4282734 USD
CY2015Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
70754 USD
CY2014Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0 USD
CY2015Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
2119689 USD
CY2015Q1 mtnb Effectiveness Of Registration Statement Description
EffectivenessOfRegistrationStatementDescription
If the Registration Statement is not filed on or before the Filing Deadline or not declared effective on or before the Effectiveness Deadline, the Company shall pay to each holder of registerable securities purchased in the 2015 Private Placement an amount in cash equal to one-half of one percent (0.5%) of such holders investment amount on every thirty (30) day anniversary of such Filing Deadline or Effectiveness Deadline failure until such failure is cured. The payment amount shall be prorated for partial thirty (30) day periods. The maximum aggregate amount of payments to be made by the Company as the result of such failures, whether by reason of a Filing Deadline failure, Effectiveness Deadline failure or any combination thereof, shall be an amount equal to 6% of each holders investment amount.
CY2015Q1 mtnb Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
4282734 USD

Files In Submission

Name View Source Status
0001144204-15-031549-index-headers.html Edgar Link pending
0001144204-15-031549-index.html Edgar Link pending
0001144204-15-031549.txt Edgar Link pending
0001144204-15-031549-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mtnb-20150331.xml Edgar Link completed
mtnb-20150331.xsd Edgar Link pending
mtnb-20150331_cal.xml Edgar Link unprocessable
mtnb-20150331_def.xml Edgar Link unprocessable
mtnb-20150331_lab.xml Edgar Link unprocessable
mtnb-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v410107_10q.htm Edgar Link pending
v410107_ex31-1.htm Edgar Link pending
v410107_ex31-2.htm Edgar Link pending
v410107_ex32-1.htm Edgar Link pending